Drug intelligence / Profile preview

JKT-002

Development stage: Preclinical
Lead developer: Convalife Pharmaceutical

Overview

JKT-002 is a drug candidate initially developed by Convalife (Shanghai) Co. Ltd. It is being investigated for the treatment of infectious diseases, with its primary indication being respiratory syncytial virus (RSV) infections. As of the latest available information, JKT-002 remains in preclinical development and has not yet entered clinical trials or received regulatory approval. The specific mechanism of action, molecular target(s), and modality have not been publicly disclosed[1][2].

Beyond the preview

Go deeper on JKT-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JKT-002.

Explore the full profile